Screening for asymptomatic coronary artery disease in waitlisted kidney transplant candidates (CARSK)

Clinical practice guidelines recommend regular screening for asymptomatic coronary artery disease (CAD) in waitlisted kidney transplant candidates due to the high prevalence of cardiovascular disease in patients with end-stage kidney disease. However, the efficacy and cost-effectiveness of this practice have never been evaluated. This study aims to estimate the incremental costs and effects of no further screening compared with the current standard of care, which involves protocolised screening every 1-2 years for asymptomatic CAD after waitlist entry. A pre-trial model using current available published estimates is built to highlight areas of uncertainty to direct data collection during the main trial.

See ANZCTR for full study details >